ABT-510: Difference between revisions
Content deleted Content added
Rescuing 1 sources and tagging 0 as dead. #IABot (v1.2.4) |
|||
| Line 1: | Line 1: | ||
'''ABT-510''' is a molecular therapeutic drug that was the subject of research as a potential treatment for cancer. According to the ''Journal of Clinical Oncology'', ABT-510 is a "subcutaneously (SC) administered nonapeptide thrombospondin analogue."<ref>{{cite journal |title=2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) |journal=J. Clin. Oncol. |volume=22 |issue=14S Suppl |id=3080 |date=July 15, 2004 }}</ref><ref name="jamesline.com">[http://www.jamesline.com/cancertypes/glossary/index.cfm?action=Display&ID=367468&Letter=A NCI: ABT-510<!-- Bot generated title -->]</ref> |
'''ABT-510''' is a molecular therapeutic drug that was the subject of research as a potential treatment for cancer. According to the ''Journal of Clinical Oncology'', ABT-510 is a "subcutaneously (SC) administered nonapeptide thrombospondin analogue."<ref>{{cite journal |title=2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) |journal=J. Clin. Oncol. |volume=22 |issue=14S Suppl |id=3080 |date=July 15, 2004 }}</ref><ref name="jamesline.com">[http://www.jamesline.com/cancertypes/glossary/index.cfm?action=Display&ID=367468&Letter=A NCI: ABT-510<!-- Bot generated title -->] {{wayback|url=http://www.jamesline.com/cancertypes/glossary/index.cfm?action=Display&ID=367468&Letter=A |date=20070928054014 }}</ref> |
||
Following inconclusive [[Clinical_trial#Phase_I|phase I]] clinical trials, a 2007 [[Clinical_trial#Phase_II|phase II]] study of ABT-510 for treatment of metastatic [[melanoma]] failed to reach its primary [[Clinical endpoint|endpoint]] resulting in termination of the study. Only three out of twenty-one patients reached the primary endpoint of progression-free survival at 18 weeks, but these three patients remained progression-free for 21, 34, and 42 weeks. However, biomarker data collected during this study showed a decrease in [[VEGFC|VEGF-C]], circulating endothelial cells, and [[CD146]] and CD34/133 counts, and a maximum tolerated dose has still not been established. Further study could consider a higher dose and/or combination treatment.<ref>{{cite journal |vauthors=Markovic SN, Suman VJ, Rao RA |title=A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma |journal=Am. J. Clin. Oncol. |volume=30 |issue=3 |pages=303–9 |date=June 2007 |pmid=17551310 |doi=10.1097/01.coc.0000256104.80089.35 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0277-3732&volume=30&issue=3&spage=303|display-authors=etal}}</ref> |
Following inconclusive [[Clinical_trial#Phase_I|phase I]] clinical trials, a 2007 [[Clinical_trial#Phase_II|phase II]] study of ABT-510 for treatment of metastatic [[melanoma]] failed to reach its primary [[Clinical endpoint|endpoint]] resulting in termination of the study. Only three out of twenty-one patients reached the primary endpoint of progression-free survival at 18 weeks, but these three patients remained progression-free for 21, 34, and 42 weeks. However, biomarker data collected during this study showed a decrease in [[VEGFC|VEGF-C]], circulating endothelial cells, and [[CD146]] and CD34/133 counts, and a maximum tolerated dose has still not been established. Further study could consider a higher dose and/or combination treatment.<ref>{{cite journal |vauthors=Markovic SN, Suman VJ, Rao RA |title=A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma |journal=Am. J. Clin. Oncol. |volume=30 |issue=3 |pages=303–9 |date=June 2007 |pmid=17551310 |doi=10.1097/01.coc.0000256104.80089.35 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0277-3732&volume=30&issue=3&spage=303|display-authors=etal}}</ref> |
||
Revision as of 00:45, 1 October 2016
ABT-510 is a molecular therapeutic drug that was the subject of research as a potential treatment for cancer. According to the Journal of Clinical Oncology, ABT-510 is a "subcutaneously (SC) administered nonapeptide thrombospondin analogue."[1][2]
Following inconclusive phase I clinical trials, a 2007 phase II study of ABT-510 for treatment of metastatic melanoma failed to reach its primary endpoint resulting in termination of the study. Only three out of twenty-one patients reached the primary endpoint of progression-free survival at 18 weeks, but these three patients remained progression-free for 21, 34, and 42 weeks. However, biomarker data collected during this study showed a decrease in VEGF-C, circulating endothelial cells, and CD146 and CD34/133 counts, and a maximum tolerated dose has still not been established. Further study could consider a higher dose and/or combination treatment.[3]
References
- ^ "2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)". J. Clin. Oncol. 22 (14S Suppl). July 15, 2004. 3080.
- ^ NCI: ABT-510 Archived 2007-09-28 at the Wayback Machine
- ^ Markovic SN, Suman VJ, Rao RA, et al. (June 2007). "A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma". Am. J. Clin. Oncol. 30 (3): 303–9. doi:10.1097/01.coc.0000256104.80089.35. PMID 17551310.